Abstract
CALGB 9720 was a phase 3 trial evaluating the multidrug resistance modulator PSC-833 (Valspodar) in induction and consolidation, and subcutaneous interleukin-2 (IL-2) maintenance therapy (rx) in older AML patients (pts). The PSC-833-containing arm was closed after randomization of 120 pts due to excessive toxicity (
Blood
2002
;100
:1224
Blood
2006
;108
:63
Blood
2006
;108
:129a
Author notes
Disclosure: No relevant conflicts of interest to declare.
2007, The American Society of Hematology
2007
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal